Company news

Sight Sciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Sight Sciences Receives FDA 510(k) Clearance of the TearCare® System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease

December 21, 2021

Sight Sciences Reports Third Quarter 2021 Financial Results

November 9, 2021

Sight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled IDE Trial of Canal Viscodilation in Combination with Cataract Surgery in Adults with Primary Open-Angle Glaucoma (POAG)

November 9, 2021

Sight Sciences to Report Third Quarter 2021 Financial Results on November 10, 2021

October 26, 2021

Sight Sciences Announces TearCare® Clinical Data Published in Cornea

October 19, 2021

Sight Sciences Files Lawsuit Against Ivantis for Patent Infringement

September 15, 2021

Sight Sciences, Pioneering the Development of the Standalone MIGS Market, Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma

August 23, 2021

Sight Sciences Reports Second Quarter 2021 Financial Results

August 11, 2021

Sight Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021

August 1, 2021

Sight Sciences Announces Multiple Presentations at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting

July 21, 2021

Sight Sciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

July 18, 2021

Sight Sciences Announces Pricing of Initial Public Offering

July 13, 2021

← Newer news releases

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 23 decks. Every deck is listed under its year.